| Non-Small Cell Lung Carcinoma
Abraxane vs Cyramza
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Abraxane vs Cyramza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCyramza has a higher rate of injection site reactions vs Abraxane based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cyramza but not Abraxane, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Abraxane
Cyramza
At A Glance
IV infusion
Weekly to every 3 weeks
Microtubule inhibitor
IV infusion
Every 2 weeks
VEGFR2 antagonist
Indications
- Carcinoma breast stage IV
- Non-Small Cell Lung Carcinoma
- Adenocarcinoma of pancreas
- Gastric Adenocarcinoma
- Non-Small Cell Lung Carcinoma
- Metastasis from malignant neoplasm of colon and/or rectum
- Liver carcinoma
Dosing
Carcinoma breast stage IV 260 mg/m2 IV over 30 minutes every 3 weeks.
Non-Small Cell Lung Carcinoma 100 mg/m2 IV over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after ABRAXANE.
Adenocarcinoma of pancreas 125 mg/m2 IV over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle; administer gemcitabine on Days 1, 8, and 15 of each 28-day cycle immediately after ABRAXANE.
Gastric Adenocarcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent or in combination with weekly paclitaxel.
Non-Small Cell Lung Carcinoma (EGFR exon 19/21, first-line) 10 mg/kg every 2 weeks by IV infusion in combination with erlotinib.
Non-Small Cell Lung Carcinoma (post-platinum progression) 10 mg/kg by IV infusion on Day 1 of a 21-day cycle in combination with docetaxel.
Metastasis from malignant neoplasm of colon and/or rectum 8 mg/kg every 2 weeks by IV infusion prior to FOLFIRI.
Liver carcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent.
Contraindications
- Baseline neutrophil count below 1500 cells/mm3
- History of severe hypersensitivity reaction to ABRAXANE
—
Adverse Reactions
Most common (>=20%) Alopecia, neutropenia, sensory/peripheral neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, diarrhea, thrombocytopenia, peripheral edema, pyrexia, vomiting, decreased appetite, rash, dehydration
Serious Anemia, pneumonia, pyrexia, dehydration, vomiting
Postmarketing Severe hypersensitivity reactions, congestive heart failure, left ventricular dysfunction, atrioventricular block, pneumonitis, interstitial pneumonia, pulmonary embolism, cranial nerve palsies, vocal cord paresis, autonomic neuropathy, cystoid macular edema, hepatic necrosis, intestinal obstruction, intestinal perforation, pancreatitis, ischemic colitis, tumor lysis syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis
Most common (>=10%) Hypertension, fatigue/asthenia, neutropenia, diarrhea, epistaxis, peripheral edema, stomatitis, proteinuria, thrombocytopenia, decreased appetite, nausea.
Serious Febrile neutropenia, pneumonia, hemorrhage, gastrointestinal perforation, arterial thromboembolic events, impaired wound healing, posterior reversible encephalopathy syndrome, proteinuria including nephrotic syndrome, infusion-related reactions, sepsis.
Postmarketing Thrombotic microangiopathy, hemangioma, dysphonia, arterial aneurysms/dissections/rupture, heart failure.
Pharmacology
ABRAXANE is a microtubule inhibitor that promotes assembly and stabilization of microtubules from tubulin dimers, inhibiting the normal dynamic reorganization of the microtubule network essential for vital interphase and mitotic cellular functions.
Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands VEGF-A, VEGF-C, and VEGF-D, inhibiting ligand-stimulated activation of VEGFR2 and thereby inhibiting endothelial cell proliferation, migration, and angiogenesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Abraxane
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Cyramza
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Abraxane
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Cyramza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Abraxane
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Cyramza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Abraxane.
No savings programs available for Cyramza.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AbraxaneView full Abraxane profile
CyramzaView full Cyramza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.